Joffe, B. I., Li, G., Gorroochurn, P., DeCastro, G. J., Lenis, A. T., McKiernan, J. M., & Anderson, C. B. (2025). The impact of indocyanine green on partial nephrectomy perioperative outcomes. Journal of Robotic Surgery, 19(1). https://doi.org/10.1007/s11701-025-02242-3

Ma, L., Pang, Z., Zhang, H., Yang, X., Zheng, S., Chen, Y., Ding, W., Han, Q., Zhang, X., Cao, L., Fei, T., Wang, Q., Gao, D., He, A., Hu, K.-B., Li, X., & Sheng, R. (2025). Clear cell renal carcinoma essentially requires CDKL3 for oncogenesis. Proceedings of the National Academy of Sciences, 122(7). https://doi.org/10.1073/pnas.2415244122

Pallauf, M., Rezaee, M., Elias, R., Wlajnitz, T., Fletcher, S. A., Cheaib, J., Alkhatib, K., Chang, P., Wagner, A. A., McKiernan, J. M., Allaf, M. E., Pierorazio, P. M., & Singla, N. (2025). Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance. BJU International. Portico. https://doi.org/10.1111/bju.16651

Joffe, B. I., Martina, L. P., Stillman, M., Rust, D., Gorroochurn, P., Lenis, A. T., DeCastro, G. J., McKiernan, J. M., & Anderson, C. B. (2024). Tumor characteristics in immunosuppressed and renal dysfunction populations. Urologic Oncology: Seminars and Original Investigations, 42(12), 453.e9-453.e14. https://doi.org/10.1016/j.urolonc.2024.09.011

Singla, N., Nirschl, T. R., Obradovic, A. Z., Shenderov, E., Lombardo, K., Liu, X., Pons, A., Zarif, J. C., Rowe, S. P., Trock, B. J., Hammers, H. J., Bivalacqua, T. J., Pierorazio, P. M., Deutsch, J. S., Lotan, T. L., Taube, J. M., Ged, Y. M. A., Gorin, M. A., Allaf, M. E., & Drake, C. G. (2024). Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-51889-9

Lin, C.-C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., Maur, M., Hui, R., Soo, R. A., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D. S., Cassier, P. A., Sarantopoulos, J., Weickhardt, A., Carvajal, R. D., Spratlin, J., … De Braud, F. (2023). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2023.2290787

de Oliveira, W. E., Murra, M. S., Tufi, L. M. B., Cavalcante, C. E. B., de Oliveira, M. A., da Costa, R. F. A., Rosa, B. R., da Silva, R. Z. M., Ribeiro, R. C., Ladas, E. J., & Barr, R. D. (2023). Sarcopenia in Children With Wilms Tumor: A Marker of Undernutrition Which May Impact Adversely on Clinical Outcomes. Journal of Pediatric Hematology/Oncology, 45(7), e817–e822. https://doi.org/10.1097/mph.0000000000002732

Ager, C. R., Zhang, M., Chaimowitz, M., Bansal, S., Tagore, S., Obradovic, A., Jugler, C., Rogava, M., Melms, J. C., McCann, P., Spina, C., Drake, C. G., Dallos, M. C., & Izar, B. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer, 11(9), e006782. https://doi.org/10.1136/jitc-2023-006782

Chung, R., Kurtzman, J. T., Gillespie, A., Martina, L. P., Wang, C., McKiernan, J. M., & Anderson, C. B. (2023). The Utility of Renal Mass Biopsy in Shared Decision-Making for Renal Mass Treatment. Urology, 178, 98–104. https://doi.org/10.1016/j.urology.2023.04.023

Unachukwu, U., Sonett, J., Woode, D., Shiomi, T., Chada, K., & D’Armiento, J. M. (2023). Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis. Molecular Cancer Therapeutics, 22(7), 844–858. https://doi.org/10.1158/1535-7163.mct-22-0224

Dason, S., Lacuna, K., Hannan, R., Singer, E. A., & Runcie, K. (2023). State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book, 43. https://doi.org/10.1200/edbk_390038

Goodstein, T., Yang, Y., Runcie, K., Srinivasan, R., & Singer, E. A. (2023). Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. Current Opinion in Oncology, 35(3), 206–217. https://doi.org/10.1097/cco.0000000000000939

Wolfe, D. M., Webster Carrion, A., Masukhani, M. M., Oberg, J. A., Pavisic, J., El-Ali, A., Gupta, M., Weng, K., & Glasser, C. L. (2022). Concurrent Hepatoblastoma and Wilms Tumor Leading to Diagnosis of Beckwith-Wiedemann Syndrome. Journal of Pediatric Hematology/Oncology, 45(4), e525–e529. https://doi.org/10.1097/mph.0000000000002593

Rancan, C., Arias-Badia, M., Dogra, P., Chen, B., Aran, D., Yang, H., Luong, D., Ilano, A., Li, J., Chang, H., Kwek, S. S., Zhang, L., Lanier, L. L., Meng, M. V., Farber, D. L., & Fong, L. (2023). Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function. Nature Immunology, 24(4), 612–624. https://doi.org/10.1038/s41590-023-01448-7

Han, D. S., Johnson, J. P., Schulster, M. L., & Shah, O. (2022). Indications for and results of renal autotransplantation. Current Opinion in Nephrology & Hypertension, 32(2), 183–192. https://doi.org/10.1097/mnh.0000000000000860

Wayne, G., Wei, J., Demus, T., Okhawere, K. E., Atri, E., Wong, V., Badani, K., & Bhandari, A. (2022). Moving away from mannitol infusion for partial nephrectomy: has this altered renal function? Journal of Robotic Surgery. https://doi.org/10.1007/s11701-022-01397-7

Coutinho, D. F., Mundi, P. S., Marks, L. J., Burke, C., Ortiz, M. V., Diolaiti, D., Bird, L., Vallance, K. L., Ibáñez, G., You, D., Long, M., Rosales, N., Grunn, A., Ndengu, A., Siddiquee, A., Gaviria, E. S., Rainey, A. R., Fazlollahi, L., Hosoi, H., … Dela Cruz, F. S. (2022). Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. Med, 3(11), 774-791.e7. https://doi.org/10.1016/j.medj.2022.09.002

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147

Wallace, B. K., Miles, C. H., & Anderson, C. B. (2022). Effects of race and socioeconomic status on treatment for localized renal masses in New York City. Urologic Oncology: Seminars and Original Investigations, 40(2), 65.e19-65.e26. https://doi.org/10.1016/j.urolonc.2021.11.004